Joel Beatty

Stock Analyst at Baird

(4.58)
# 225
Out of 5,157 analysts
211
Total ratings
51.2%
Success rate
34.13%
Average return

Stocks Rated by Joel Beatty

Dianthus Therapeutics
Mar 10, 2026
Maintains: Outperform
Price Target: $67$132
Current: $86.92
Upside: +51.86%
Contineum Therapeutics
Mar 6, 2026
Maintains: Outperform
Price Target: $14$20
Current: $13.41
Upside: +49.14%
Praxis Precision Medicines
Feb 20, 2026
Maintains: Outperform
Price Target: $275$433
Current: $309.91
Upside: +39.72%
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $72$47
Current: $22.84
Upside: +105.78%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $160$209
Current: $185.93
Upside: +12.41%
e.l.f. Beauty
Nov 6, 2025
Maintains: Outperform
Price Target: $145$125
Current: $80.49
Upside: +55.30%
Amylyx Pharmaceuticals
Oct 16, 2025
Maintains: Outperform
Price Target: $10$19
Current: $14.98
Upside: +26.84%
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $10$7
Current: $5.61
Upside: +24.78%
Editas Medicine
Aug 13, 2025
Maintains: Outperform
Price Target: $4$6
Current: $2.64
Upside: +127.27%
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7$9
Current: $36.68
Upside: -75.46%
Maintains: Outperform
Price Target: $28$31
Current: $22.54
Upside: +37.53%
Downgrades: Neutral
Price Target: $38$24
Current: $23.07
Upside: +4.03%
Upgrades: Outperform
Price Target: $680
Current: $742.79
Upside: -8.45%
Maintains: Outperform
Price Target: $30$29
Current: $21.43
Upside: +35.32%
Maintains: Outperform
Price Target: $70$66
Current: $68.56
Upside: -3.73%
Maintains: Outperform
Price Target: $160$162
Current: $166.34
Upside: -2.61%
Maintains: Outperform
Price Target: $38$41
Current: $27.74
Upside: +47.80%
Maintains: Outperform
Price Target: $28$32
Current: $24.77
Upside: +29.19%
Initiates: Outperform
Price Target: $75
Current: $79.63
Upside: -5.81%
Maintains: Outperform
Price Target: $6$7
Current: $2.76
Upside: +153.62%
Maintains: Neutral
Price Target: $72$65
Current: $60.89
Upside: +6.75%
Maintains: Outperform
Price Target: $540$240
Current: $0.36
Upside: +66,566.67%
Downgrades: Neutral
Price Target: $4.5
Current: $1.63
Upside: +176.07%
Maintains: Outperform
Price Target: $24$25
Current: $15.90
Upside: +57.23%
Maintains: Outperform
Price Target: $32$28
Current: $24.16
Upside: +15.89%
Initiates: Outperform
Price Target: $16
Current: $1.28
Upside: +1,150.00%
Maintains: Outperform
Price Target: $4$1.25
Current: $1.47
Upside: -14.97%
Initiates: Outperform
Price Target: $44
Current: $1.39
Upside: +3,065.47%
Maintains: Outperform
Price Target: $60$58
Current: $59.20
Upside: -2.03%
Maintains: Outperform
Price Target: $18$24
Current: $34.74
Upside: -30.92%
Downgrades: Underperform
Price Target: $18
Current: $7.62
Upside: +136.22%
Maintains: Outperform
Price Target: $9$6
Current: $2.02
Upside: +197.03%
Upgrades: Neutral
Price Target: $36$28
Current: $9.88
Upside: +183.40%
Downgrades: Neutral
Price Target: $170$175
Current: $322.38
Upside: -45.72%
Downgrades: Neutral
Price Target: $14
Current: $9.56
Upside: +46.44%
Downgrades: Neutral
Price Target: $108
Current: $17.66
Upside: +511.55%
Maintains: Buy
Price Target: $80$78
Current: $75.66
Upside: +3.09%
Maintains: Buy
Price Target: $140$100
Current: $23.54
Upside: +324.81%
Maintains: Buy
Price Target: $480$120
Current: $15.97
Upside: +651.64%
Maintains: Buy
Price Target: $480$450
Current: $4.66
Upside: +9,556.65%
Upgrades: Buy
Price Target: n/a
Current: $2.70
Upside: -
Maintains: Buy
Price Target: $19$15
Current: $10.69
Upside: +40.32%
Upgrades: Neutral
Price Target: $14$11
Current: $12.79
Upside: -17.90%
Maintains: Neutral
Price Target: $2,400$1,200
Current: $0.38
Upside: +318,964.08%
Maintains: Buy
Price Target: $15$19
Current: $9.26
Upside: +105.18%